Abstract
Fifteen patients with advanced carcinoma of the breast who had failed prior chemotherapy, were treated with recombinant gamma interferon at a dose of 2mg/m2 (1mg = 2.4 × 107 international units) intravenously for five consecutive days every other week. The median patient age was 51 and all patients had a performance status of 0–2 (Karnofsky ≥ 50). Thirteen patients had two or three sites of metastatic disease and seven were estrogen receptor positive. No complete or partial responses were noted. Although some patients had brief periods of stable disease, almost all patients progressed after one or two courses. Only one patient was able to receive six courses of induction therapy and a brief course of maintenance. Flu-like symptoms and nausea were seen in all patients; vomiting and anorexia were frequent. Hepatic toxicity manifested by enzyme elevation was common and was most severe in patients with liver metastases. In this study a highly purified biologically active gamma interferon was not associated with anti-tumor activity in previously treated women with metastatic breast cancer.
Similar content being viewed by others
References
Balkwill F, Taylor-Papadimitriou J, Fantes KH, Sebesteny A: Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) mice. Eur J Cancer 16:569–573, 1980
Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol 2:336–352, 1984
Gutterman J, Blumenschein R, Alexanian R, Yap H-Y, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93:399–406, 1980
Borden E, Holland JF, Dao T, Gutterman JU, Wiener L, Chang Y-C, Patel J: Leukocyte-derived interferon (alpha) in human breast carcinoma: The American Cancer Society phase II trial. Ann Intern Med 97:1–6, 1982
Quesada JR, Gutteman JU, Hersh EM: Clinical and immunological study of beta interferon by intramuscular route in patients with metastatic breast cancer. Interferon Res 2:593–599, 1982
Sherwin SA, Mayer D, Ochs JJ, Abrams PG, Knost JA, Foon KA, Fein S, Oldham RK: Recombinant leukocyte A interferon in advanced breast cancer. Ann Intern Med 98:598–602, 1983
Muss HB, Kempf RA, Martino S, Rudnick SA, Greiner J, Cooper MR, Decker D, Grunberg SM, Jackson DV, Richards F II, Samal B, Singhakowinta A, Spurr CL, Stuart JJ, White DR, Caponera M, Mitchell MS: A phase II study of recombinant α interferon in patients with recurrent metastatic breast cancer. J Clin Oncol 2:1012–1016, 1984
Nethersell A, Smedley H, Katrak M, Wheeler T, Sikora K: Recombinant interferon in advanced breast cancer. Br J Cancer 49:615–620, 1984
Sarna GP, Figlin RA: Phase II trial of α-lymphoblastoid interferon given weekly as treatment of advanced breast cancer. Cancer Treat Rep 69:547–549, 1985
Harada M, Matsumoto M: Preclinical studies of recombinant human interferon gamma: Effects on NK and ADCC activiities of human peripheral blood lymphocytes. Shionogi Res Lab, Fukashima-Ku, Osaka, Japan 1983
Rubin BY, Gupta SL: Differential effects of human type I and type II interferons as antiviral and antiproliferative agents. Proc Natl Acad Sci USA 77(10):5928–5932, 1980
Blalock JE, Georgiades JA, Langford MP, Johnson HM: Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Cell Immunol 49:390–394, 1980
Hayward JL, Carbone PP, Heuson JC, Kumaokas SA, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289–1293, 1977
Miller B, Hoogstraten B, Staquet M, Winker A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Liang C-M, Herren S, Fountoulakis M, Otto B, Hirschi M, Gutzwiller E, Gerlis L: Analysis of antibody response in patients receiving recombinant Escherichia coli-derived human interferon-gamma. Clin Immunol Immunopath 36:95–100, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Muss, H.B., Caponera, M., Zekan, P.J. et al. Recombinant gamma interferon in advanced breast cancer: A phase II trial. Invest New Drugs 4, 377–381 (1986). https://doi.org/10.1007/BF00173511
Issue Date:
DOI: https://doi.org/10.1007/BF00173511